Myeloproliferative Neoplasms (MPNs)
Living Well With MPNs
The expert panel featured renowned MPN specialist and researcher Dr. Ruben Mesa and was joined by other experienced clinicians and patients on the broadcast, to share knowledge and advice about the benefits of a healthy lifestyle when dealing with myeloproliferative neoplasms (MPNs).
What new treatments are in development for myeloproliferative neoplasms (MPNs)? What are the considerations when choosing a treatment plan? In this LIVE webinar, Dr. Bart Scott from Seattle Cancer Care Alliance and Dr. David Snyder from City of Hope will help viewers to understand the various treatment options for those living with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF).
Should you get a genetic test? JAK2, MPL, CALR, ASXL1: Mutations associated with myeloproliferative neoplasms (MPNs) can bring up lots of questions. What do they mean, and how do they impact your disease? The goal of this webinar, featuring Dr. Alison Moliterno from Johns Hopkins School of Medicine and Dr. Stephen Oh from Washington University School of Medicine, is to help patients understand genetic mutations.
Ask the Expert
Patient Cafe® MPN
Town Meeting Videos
Interview with Carmelita P. Escalante, MD, FACP, Professor and Chair Department of General Internal Medicine The University of Texas MD Anderson Cancer Center
Interview with Olatoyosi Odenike, MD, Associate Professor of Medicine University of Chicago Medical Center and Srdan Verstovsek, MD, PhD, Professor, Department of Leukemia, Division of Cancer Medicine
The Conversation - Polycythemia Vera (PV)
Research is ever improving for Polycythemia Vera. Dr. Verstovsek, Dr. Heaney and Bob Rosen all agree that the future looks positive for PV patients. A discussion follows about current and future treatment options.
Patient Advocate, Vocille "Peppe" Fryou, shares her cancer journey. Even with 10 years without a diagnosis and several clinical trials, Peppe has persevered and has high hopes for the future.
In an exclusive interview at the American Society of Hematology meeting, Dr. Naveen Pemmaraju talks about results of the phase 3 COMFORT - II trial for myelofibrosis comparing the use of a JAK inhibitor, ruxolitinib, to standard care. Dr. Pemmaraju then mentions another trial evaluating the use of Pacritinib, a new, not yet FDA approved JAK inhibitor that also showed promising results. In closing, Dr. Pemmaraju encourages patients with MPNs to talk with their doctor about clinical trials as a viable treatment option.